Compare Rigetti Computing Inc (RGTI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs TG Therapeutics Inc — how do they compare? Rigetti Computing Inc trades at $14.03 (market cap $4.72B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rigetti Computing Inc for 35 Days and TG Therapeutics Inc for 16 Days on average.
| RGTI | TGTX | |
|---|---|---|
Market Cap | $4.72B | $8.16B |
Volume | 17,136,381 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $56.34 | $59.06 |
52-Week Low | $12.90 | $26.94 |
Typical Hold Time | 35 Days | 16 Days |
Enterprise Value | $4.33B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGTI trades at $14.14, down 3.08% today, amid bearish technical signals despite bullish oscillators. The company shows negative profitability with a -1,787.4% net income margin and -$216.21M net loss for 2025, though revenue grew to $13M in 2026. Recent news highlights Rigetti's hybrid quantum-HPC strategy advancements and sector momentum from IonQ's developments.
Wall Street maintains strong bullish sentiment with 6 buy ratings and a $21.67 price target, representing 53% upside. However, significant execution risks persist given negative cash flow, high valuation multiples, and intense quantum computing competition. The stock offers high-risk growth potential for investors comfortable with speculative emerging technology plays.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
